TCR Cure provides R&D and industrialization of tumor immune cell therapy technology with engineered T cells as the ultimate target. With the development of a series of CAR-T, TCR-T, CAR-NK, and TIL immune cell therapy products, the cure rate of tumors is improved, and the mortality rate, recurrence rate, and disability rate of tumors are